Showing 1871-1880 of 3223 results for "".
- Alcon Introduces Reusable Toric Lens with Launch of TOTAL30 for Astigmatismhttps://modernod.com/news/alcon-introduces-reusable-toric-lens-with-launch-of-total30-for-astigmatism/2481324/Alcon announced plans to launch TOTAL30 for Astigmatism, which the company calls the first-and-only reusable contact lens with water gradient material for astigmatic contact lens wearers. Using Alcon’s proprietary water gradient material, first introduced with DAILIES TOTAL1&
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Aldeyra Therapeutics Submits NDA to FDA for ADX‑2191 for Treatment of Primary Vitreoretinal Lymphomahttps://modernod.com/news/aldeyra-therapeutics-submits-new-drug-application-to-fda-for-adx2191-for-treatment-of-primary-vitreoretinal-lymphoma-1/2481306/Aldeyra Therapeutics announced the submission of a new drug application (NDA) to the FDA for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.</
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.
- AI-Diagnostics Startup Altris AI Raises $1 Million to Scale AI-Based Eye Care Diagnostics Platformhttps://modernod.com/news/ai-diagnostics-startup-altris-ai-raises-1-million/2481296/Altris AI announced it has raised $1 million to scale its AI-enabled eye care diagnostics solution. Altris AI, which is a US-based startup originally from Ukraine, developed a SaaS platform based on 5 million OCT scans that detected and interpreted more than 100 pathologies an
- Aldeyra Therapeutics Submits NDA to the FDA for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-submits-nda-to-the-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2481263/Aldeyra Therapeutics announced the submission of a new drug application (NDA) to the FDA for topical ocular reproxalap, an investigational new drug candidate for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseaseshttps://modernod.com/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001-for-retinal-diseases/2481256/Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-relat
- Medicontur Launches Bi-Flex Elon Nondiffractive EDOF IOLhttps://modernod.com/news/medicontur-launches-bi-flex-elon-nondiffractive-edof-iol/2481224/Medicontur announced the launch of the Bi-Flex Elon Nondiffractive EDOF IOL. The Elon, which was launched on September 6, features proprietary Wavefront Linking technology that is designed to create a true elongated focus with minimal optical disturbances. This non-d
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in the Czech Republichttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-the-czech-republic/2481212/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis, through its distribu